Given the intricate pathogenesis of gastric cancer and the limited efficacy of current metastasis‐targeted interventions, innovative therapeutic strategies—such as circRNA‐based modulation, OGT inhibitors, and DYRK1A kinase‐targeted therapy—are urgently needed. This evidence concerns the gene OGT and gastric cancer.